2026-05-14T15:11:47Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/226192024-09-06T10:49:18Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16980
Repisalud
author
Sauleda, Jaume
author
Núñez, Belén
author
Sala, Ernest
author
Soriano, Joan B
2024-09-06T09:56:41Z
2024-09-06T09:56:41Z
2018
Sauleda J, Nunez B, Sala E, Soriano JB. Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes.. Med Sci (Basel). 2018;6(4). 2018 Nov 29.
10.3390/medsci6040110
2076-3271
Medical Sciences (Basel, Switzerland)
http://hdl.handle.net/20.500.13003/17088
30501130
L640463172
2-s2.0-85149155256
https://hdl.handle.net/20.500.12105/22619
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is characterized by a chronic, progressive, fibrotic interstitial lung disease of unknown cause that occurs primarily in older adults. Its prevalence and incidence have appeared to be increasing over the last decades. Despite its unknown nature, several genetic and environmental factors have been associated with IPF. Moreover, its natural history is variable, but could change depending on the currently suggested phenotypes: rapidly progressive IPF, familial, combined pulmonary fibrosis and emphysema, pulmonary hypertension, and that associated with connective tissue diseases. Early recognition and accurate staging are likely to improve outcomes and induce a prompt initiation of antifibrotics therapy. Treatment is expected to be more effective in the early stages of the disease, while developments in treatment aim to improve the current median survival of 3?4 years after diagnosis.
eng
comorbidities
evolution
idiopathic pulmonary fibrosis
incidence
prevalence
risk factors
Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes.
review article